The Trump administration sued Walmart Inc. WMT -1.36% Tuesday, accusing the retail giant of helping to fuel the nation’s opioid crisis by inadequately screening for questionable prescriptions despite repeated warnings from its own pharmacists.
The Justice Department’s lawsuit claims that Walmart sought to boost profits by understaffing its pharmacies and pressuring employees to fill prescriptions quickly. That made it difficult for pharmacists to reject invalid prescriptions, enabling widespread drug abuse nationwide, the suit alleges
Walmart didn’t immediately respond to a request for comment.
The country’s largest retailer by revenue, Walmart has been expecting this complaint and sued the federal government in October to fight the allegations pre-emptively.
In its suit, Walmart accuses the Justice Department and Drug Enforcement Administration of attempting to scapegoat the company for what it says are the federal government’s own regulatory and enforcement shortcomings.
The Justice Department’s lawsuit alleges Walmart created a system that turned its network of 5,000 in-store U.S. pharmacies into a leading supplier of highly addictive painkillers. The allegations date to June 2013, according to the suit.
Walmart started with cut-rate prices on opioids that initially drove shoppers to its stores, the government alleges. Middle managers—under direction from executives at company headquarters—pressured their pharmacists to work faster, the suit says, believing that quick-fill prescriptions drew customers to stay and keep shopping.
Many of the alleged problems centered in Walmart’s compliance unit, which oversaw dispensing nationwide from the company’s main office in Bentonville, Ark., the suit says. Walmart ignored repeated warnings that the company had understaffed its pharmacies, and that pressure to sell quickly was leading to mistakes and putting patient health at risk, according to the complaint.
The U.S. lawsuit said this system made it difficult for pharmacists to reject prescriptions from doctors who intentionally overprescribe and, when they did, the customers would often just go to a different Walmart. Pharmacists got little help from compliance managers who for years didn’t share information between stores and in many cases refused requests to give blanket rejections to suspect prescribers even when rival retailers already had done so, the suit alleges.
“Rather than analyzing the refusal-to-fill reports, the compliance unit viewed ‘[d]riving sales and patient awareness’ as ‘a far better use of our Market Directors and Market Manager’s time,’” the Justice Department said, quoting a company compliance director. “Given the nationwide scale of those violations, Walmart’s failures to follow basic legal rules helped fuel a national crisis.”
The Justice Department is taking action to help get Walmart to recognize the role it must have in fighting the opioid crisis, Jeffrey Clark, acting chief of the department’s Civil Division, said in an interview.
“It’s not isolated or left off the hook just because the pill-mill doctor writes the prescription,” Mr. Clark said. “Pharmacists have a duty not to just fill whatever prescription comes in the door.”
Walmart, in its suit, is seeking a declaration from a federal judge that the government has no lawful basis for seeking civil damages for the types of actions the Justice Department now alleges. The suit names the department and Attorney General William Barr as defendants, as well as the DEA and its acting administrator, Timothy Shea.
The Justice Department previously launched a parallel criminal investigation, based out of the U.S. attorney’s office for the Eastern District of Texas, related to Walmart’s dispensing of opioids. The department’s leadership in Washington decided in 2018 against bringing charges, focusing instead on a civil lawsuit, according to a person familiar with the matter.
The U.S. saw about 50,000 fatal opioid overdoses in 2019, according to federal data, a record high that reversed what had been a brief reprieve from steady increases a year earlier.
The Centers for Disease Control and Prevention said last week that there is mounting evidence the crisis is worsening even further during the Covid-19 pandemic, which has complicated treatment while increasing isolation and stress.
President Trump has pushed the Justice Department to take action against companies, though primarily opioid makers. In 2018 he asked then-Attorney General Jeff Sessions to bring the federal government’s own “major lawsuit” against drug companies that “are really sending opioids at a level that it shouldn’t be happening.”
Since then, Purdue Pharma LP has pleaded guilty to three federal felonies related to the marketing and distribution of its powerful opioid painkiller OxyContin. That came as part of an $8.34 billion settlement with the Justice Department.
Purdue is one of three drugmakers to file for bankruptcy in recent years to negotiate a settlement of hundreds of lawsuits. Counties and states are also nearing a $26 billion opioid settlement with drugmaker Johnson & Johnson and three major drug distributors.
Walmart is one of several other large companies that have been targeted in such lawsuits, filed by more than two dozen states and many local governments that claim aggressive marketing of prescription painkillers helped fuel the crisis. About 3,000 of the cases have been consolidated in a federal court in Ohio, where a judge has pressed both sides to settle for nearly three years.
The federal government’s lawsuit portrays a company in which line pharmacists allegedly were often stressed out by the combined pressure they felt from managers and from an unfolding crisis they witnessed firsthand. Alleged company orders to work quickly didn’t allow them to scrutinize each suspect prescription, and they repeatedly sought permission to use blanket rejections against clinics they believed to be obvious pill mills, the suit says.
“If all of us got together and started filling out refusal to fill” forms for one pill-mill prescriber, “that is all we would do all day long,” one Walmart pharmacy manager in Texas wrote in an Feb. 6, 2015, email to a director in the compliance unit, the suit says. “Other chains are refusing to fill for him which makes our burden even greater. Please help us.”
The compliance unit allegedly rejected that request and many others, telling pharmacists they could decide only on a case-by-case basis, according to the suit. That effectively led Walmart pharmacists to supply abusers—and encouraged more doctors to send patients to Walmart pharmacies—the government alleges, because they didn’t have time to review and complete the required paperwork for thousands of individual rejections.
Walmart later reversed course and allowed blanket rejections for suspect prescribers, the suit says. It doesn’t say when, other than to note that the company followed other major grocers and pharmacy chains that gave that power to their pharmacists already.
In its own lawsuit, Walmart said nearly 70% of the doctors that the federal government identified as problematic continue to have active DEA registrations, the company said.
“In other words, defendants want to blame Walmart for continuing to fill purportedly bad prescriptions written by doctors that DEA and state regulators enabled to write those prescriptions in the first place and continue to stand by today,” Walmart said in its suit.
U.S. attorneys allege Walmart’s compliance managers should have been tracking and sharing these reports from their own line pharmacists to help reject these prescriptions but didn’t do so. In its 160-page complaint, the government details 20 alleged instances in which it says Walmart ignored red flags, withheld information from its pharmacists and failed to help them reject invalid prescriptions, allowing hundreds and sometimes thousands of them to be filled.
—Sarah Nassauer contributed to this article.